studies

metastatic, hormone-sensitive prostate cancer, endocrine therapy vs. androgen deprivation therapy (ADT), meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 332 - treatments: 1099,1019,1351,1354,1352,1349,1350,1020,1353,1022,1422,1405,1367,1442,1361,1336